欢迎来到《四川大学学报(医学版)》
李舍予, 李双庆. 精准医疗下的肥胖症基础与临床研究[J]. 四川大学学报(医学版), 2017, 48(1): 1-6.
引用本文: 李舍予, 李双庆. 精准医疗下的肥胖症基础与临床研究[J]. 四川大学学报(医学版), 2017, 48(1): 1-6.

精准医疗下的肥胖症基础与临床研究

  • 摘要: 肥胖在我国和世界范围均已成为严重的健康问题。在人类进入精准医学时代,随着基因组学等分子生物学的技术进步,肥胖的基础与临床研究取得了很大的进展。但由于肥胖是大量异质性很大的疾病群构成,随着精准医学研究的深入,对曾经认同的肥胖的诊断和分类提出了诸多挑战,目前仍缺少可用于临床实践和商业化的疾病预测模型。在肥胖研究中,经典细胞因子和脂肪因子外的胃肠激素及相关分子、摄食相关信号通路蛋白等蛋白分子标志物和肠道基因组学等分子生物学研究是精准医疗研究的基础,加强整合个体化及群体性的分子生物学和遗传学研究,最终为肥胖症在精准医疗下向临床应用转化奠定基础。

     

    Abstract: Obesity now already becomes a critical health problem in our country and the world. Since the genomic and biochemical technology has developed in the era of precision medicine, great progression has been achieved in the field of obesity research and clinical practice. Obesity is considered to be a series of diseases with high heterogeneity beyond expectations, which brings up the challenges on its diagnosis and classification. Predictive models for obesity remain absent in clinical practice and commercial use. It is important to further understand the roles of gastric hormones and related molecules, proteins in feeding and reward system, as well as gut microbiota in obesity and associated diseases. The diagnosis and treatment of obesity require further progression in molecular biology and genetics with fruitful investigation of precision medicine, which might help the clinical translation in future.

     

© 2017 《四川大学学报(医学版)》编辑部 版权所有 cc

开放获取 本文遵循知识共享署名—非商业性使用4.0国际许可协议(CC BY-NC 4.0),允许第三方对本刊发表的论文自由共享(即在任何媒介以任何形式复制、发行原文)、演绎(即修改、转换或以原文为基础进行创作),必须给出适当的署名,提供指向本文许可协议的链接,同时标明是否对原文作了修改;不得将本文用于商业目的。CC BY-NC 4.0许可协议详情请访问 https://creativecommons.org/licenses/by-nc/4.0

/

返回文章
返回